107 related articles for article (PubMed ID: 10866315)
1. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14.
Francisco JA; Donaldson KL; Chace D; Siegall CB; Wahl AF
Cancer Res; 2000 Jun; 60(12):3225-31. PubMed ID: 10866315
[TBL] [Abstract][Full Text] [Related]
2. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.
Law CL; Gordon KA; Collier J; Klussman K; McEarchern JA; Cerveny CG; Mixan BJ; Lee WP; Lin Z; Valdez P; Wahl AF; Grewal IS
Cancer Res; 2005 Sep; 65(18):8331-8. PubMed ID: 16166310
[TBL] [Abstract][Full Text] [Related]
3. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.
Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ
Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
Tai YT; Li XF; Catley L; Coffey R; Breitkreutz I; Bae J; Song W; Podar K; Hideshima T; Chauhan D; Schlossman R; Richardson P; Treon SP; Grewal IS; Munshi NC; Anderson KC
Cancer Res; 2005 Dec; 65(24):11712-20. PubMed ID: 16357183
[TBL] [Abstract][Full Text] [Related]
5. Preclinical characterization of SGN-70, a humanized antibody directed against CD70.
McEarchern JA; Smith LM; McDonagh CF; Klussman K; Gordon KA; Morris-Tilden CA; Duniho S; Ryan M; Boursalian TE; Carter PJ; Grewal IS; Law CL
Clin Cancer Res; 2008 Dec; 14(23):7763-72. PubMed ID: 19047103
[TBL] [Abstract][Full Text] [Related]
6. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
[TBL] [Abstract][Full Text] [Related]
7. CD40 ligation of human keratinocytes inhibits their proliferation and induces their differentiation.
Péguet-Navarro J; Dalbiez-Gauthier C; Moulon C; Berthier O; Réano A; Gaucherand M; Banchereau J; Rousset F; Schmitt D
J Immunol; 1997 Jan; 158(1):144-52. PubMed ID: 8977185
[TBL] [Abstract][Full Text] [Related]
8. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.
Khubchandani S; Czuczman MS; Hernandez-Ilizaliturri FJ
Curr Opin Investig Drugs; 2009 Jun; 10(6):579-87. PubMed ID: 19513947
[TBL] [Abstract][Full Text] [Related]
9. Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates.
Kelley SK; Gelzleichter T; Xie D; Lee WP; Darbonne WC; Qureshi F; Kissler K; Oflazoglu E; Grewal IS
Br J Pharmacol; 2006 Aug; 148(8):1116-23. PubMed ID: 16847437
[TBL] [Abstract][Full Text] [Related]
10. Generation and characterization of a novel anti-rat CD40L antibody with inhibitory activities in vitro and in vivo.
Stax AM; Gelderman KA; Kamerling SW; van der Geest R; Schlagwein N; van Kooten C
J Immunol Methods; 2008 Jun; 335(1-2):46-52. PubMed ID: 18384807
[TBL] [Abstract][Full Text] [Related]
11. Ligation of CD40 influences the function of human Ig-secreting B cell hybridomas both positively and negatively.
Bergman MC; Attrep JF; Grammer AC; Lipsky PE
J Immunol; 1996 May; 156(9):3118-32. PubMed ID: 8617932
[TBL] [Abstract][Full Text] [Related]
12. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
Honeychurch J; Glennie MJ; Illidge TM
Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
[TBL] [Abstract][Full Text] [Related]
13. Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and gamma-radiation-induced apoptosis by CD40 activation.
Zhou ZH; Shi Q; Wang JF; Chen YJ; Zhuang YM; Pan JZ; Xu CS; Qi CJ; Zhang XG
Apoptosis; 2005 Jan; 10(1):123-34. PubMed ID: 15711928
[TBL] [Abstract][Full Text] [Related]
14. CD40.FasL inhibits human T cells: evidence for an auto-inhibitory loop-back mechanism.
Dranitzki-Elhalel M; Huang JH; Sasson M; Rachmilewitz J; Parnas M; Tykocinski ML
Int Immunol; 2007 Apr; 19(4):355-63. PubMed ID: 17314083
[TBL] [Abstract][Full Text] [Related]
15. Distinct apoptotic signaling characteristics of the anti-CD40 monoclonal antibody dacetuzumab and rituximab produce enhanced antitumor activity in non-Hodgkin lymphoma.
Lewis TS; McCormick RS; Emmerton K; Lau JT; Yu SF; McEarchern JA; Grewal IS; Law CL
Clin Cancer Res; 2011 Jul; 17(14):4672-81. PubMed ID: 21610152
[TBL] [Abstract][Full Text] [Related]
16. CD40 ligand stimulation inhibits the proliferation of mantle cell lymphoma lines.
Jin Z; Teramoto N; Hayashi K; Liu YX; Jin G; Oka T; Takahashi K; Yoshino T; Akagi T
Anticancer Res; 2004; 24(2B):691-7. PubMed ID: 15161013
[TBL] [Abstract][Full Text] [Related]
17. Production and characterization of agonistic monoclonal antibodies against chicken CD40.
Chen CH; Abi-Ghanem D; Njongmeta L; Bray J; Mwangi W; Waghela SD; McReynolds JL; Ing NH; Berghman LR
Dev Comp Immunol; 2010 Nov; 34(11):1139-43. PubMed ID: 20599554
[TBL] [Abstract][Full Text] [Related]
18. Agonistic and antagonistic properties of CD40 mAb G28-5 are dependent on binding valency.
Ledbetter JA; Grosmaire LS; Hollenbaugh D; Aruffo A; Nadler SG
Circ Shock; 1994 Oct; 44(2):67-72. PubMed ID: 7743602
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299.
Ho L; Aytac U; Stephens LC; Ohnuma K; Mills GB; McKee KS; Neumann C; LaPushin R; Cabanillas F; Abbruzzese JL; Morimoto C; Dang NH
Clin Cancer Res; 2001 Jul; 7(7):2031-40. PubMed ID: 11448921
[TBL] [Abstract][Full Text] [Related]
20. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
Tai YT; Li X; Tong X; Santos D; Otsuki T; Catley L; Tournilhac O; Podar K; Hideshima T; Schlossman R; Richardson P; Munshi NC; Luqman M; Anderson KC
Cancer Res; 2005 Jul; 65(13):5898-906. PubMed ID: 15994968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
